SCHEMBL3015032

SCHEMBL3015032

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALDH1A1 P00352 4/20 0.43
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
ALDH3A1 P30838 1/20 0.39
THRB P10828 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
TP53 P04637 1/20 0.39
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017217 0.93 LPAR1 (0.44) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3019609 0.90 MAPT (0.45) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL2999037 0.90 ALDH1A1 (0.46) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3020197 0.90 MAPT (0.51) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3012911 0.90 ALDH1A1 (0.48) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3002366 0.90 LMNA (0.39) MAPTLMNANPSR1ALDH1A1L3MBTL1
SCHEMBL3016519 0.90 MAPT (0.43) MAPTLMNANPSR1ALDH1A1TP53
SCHEMBL3651939 0.89 MAPT (0.48) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3016123 0.89 MAPT (0.45) MAPTLMNANPSR1ALDH1A1TSHR
SCHEMBL3006655 0.89 MAPT (0.45) MAPTLMNANPSR1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885NPSR1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.